157 related articles for article (PubMed ID: 30107087)
1. Molecular dynamic simulations of the catalytic subunit of calpains 1, 2, 5, and 10: Structural analysis with an aim toward drug design.
Romo-Mancillas A; Lemus R; Pérez-Estrada R; Kuribreña-Romero de Terreros F; Domínguez-Ramírez L
Chem Biol Drug Des; 2019 Jan; 93(1):38-49. PubMed ID: 30107087
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of allosteric calpain-1 inhibitors populating a novel bioactivity space.
Kalash L; Cresser-Brown J; Habchi J; Morgan C; Miller DJ; Glen RC; Allemann RK; Bender A
Eur J Med Chem; 2018 Sep; 157():1264-1275. PubMed ID: 30195237
[TBL] [Abstract][Full Text] [Related]
3. Calpain inhibition by alpha-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography.
Cuerrier D; Moldoveanu T; Inoue J; Davies PL; Campbell RL
Biochemistry; 2006 Jun; 45(24):7446-52. PubMed ID: 16768440
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for possible calcium-induced activation mechanisms of calpains.
Reverter D; Strobl S; Fernandez-Catalan C; Sorimachi H; Suzuki K; Bode W
Biol Chem; 2001 May; 382(5):753-66. PubMed ID: 11517928
[TBL] [Abstract][Full Text] [Related]
5. The crystal structures of human calpains 1 and 9 imply diverse mechanisms of action and auto-inhibition.
Davis TL; Walker JR; Finerty PJ; Mackenzie F; Newman EM; Dhe-Paganon S
J Mol Biol; 2007 Feb; 366(1):216-29. PubMed ID: 17157313
[TBL] [Abstract][Full Text] [Related]
6. In silico affinity profiling of neuroactive polyphenols for post-traumatic calpain inactivation: a molecular docking and atomistic simulation sensitivity analysis.
Kumar P; Choonara YE; Pillay V
Molecules; 2014 Dec; 20(1):135-68. PubMed ID: 25546626
[TBL] [Abstract][Full Text] [Related]
7. Developments in the design and synthesis of calpain inhibitors.
Neffe AT; Abell AD
Curr Opin Drug Discov Devel; 2005 Nov; 8(6):684-700. PubMed ID: 16312145
[TBL] [Abstract][Full Text] [Related]
8. The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium.
Strobl S; Fernandez-Catalan C; Braun M; Huber R; Masumoto H; Nakagawa K; Irie A; Sorimachi H; Bourenkow G; Bartunik H; Suzuki K; Bode W
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):588-92. PubMed ID: 10639123
[TBL] [Abstract][Full Text] [Related]
9. The major calpain isozymes are long-lived proteins. Design of an antisense strategy for calpain depletion in cultured cells.
Zhang W; Lane RD; Mellgren RL
J Biol Chem; 1996 Aug; 271(31):18825-30. PubMed ID: 8702541
[TBL] [Abstract][Full Text] [Related]
10. Predictions of Cleavability of Calpain Proteolysis by Quantitative Structure-Activity Relationship Analysis Using Newly Determined Cleavage Sites and Catalytic Efficiencies of an Oligopeptide Array.
Shinkai-Ouchi F; Koyama S; Ono Y; Hata S; Ojima K; Shindo M; duVerle D; Ueno M; Kitamura F; Doi N; Takigawa I; Mamitsuka H; Sorimachi H
Mol Cell Proteomics; 2016 Apr; 15(4):1262-80. PubMed ID: 26796116
[TBL] [Abstract][Full Text] [Related]
11. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
[TBL] [Abstract][Full Text] [Related]
12. Calpains: attractive targets for the development of synthetic inhibitors.
Pietsch M; Chua KC; Abell AD
Curr Top Med Chem; 2010; 10(3):270-93. PubMed ID: 20166953
[TBL] [Abstract][Full Text] [Related]
13. Comparison of calpains from rabbit, monkey, human and rat.
Kawashima S; Akanuma H; Asaoka K
Biol Chem; 1998 Feb; 379(2):201-4. PubMed ID: 9524072
[TBL] [Abstract][Full Text] [Related]
14. Modulators of calpain activity: inhibitors and activators as potential drugs.
Dókus LE; Yousef M; Bánóczi Z
Expert Opin Drug Discov; 2020 Apr; 15(4):471-486. PubMed ID: 32022614
[No Abstract] [Full Text] [Related]
15. [Molecular evolution of intracellular Ca2+-dependent proteases].
Bondareva LA; Nemova NN
Bioorg Khim; 2008; 34(3):295-302. PubMed ID: 18672675
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing between calpain heterodimerization and homodimerization.
Ravulapalli R; Campbell RL; Gauthier SY; Dhe-Paganon S; Davies PL
FEBS J; 2009 Feb; 276(4):973-82. PubMed ID: 19215300
[TBL] [Abstract][Full Text] [Related]
17. m-Calpain activation in vitro does not require autolysis or subunit dissociation.
Chou JS; Impens F; Gevaert K; Davies PL
Biochim Biophys Acta; 2011 Jul; 1814(7):864-72. PubMed ID: 21549862
[TBL] [Abstract][Full Text] [Related]
18. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin.
Hanna RA; Campbell RL; Davies PL
Nature; 2008 Nov; 456(7220):409-12. PubMed ID: 19020623
[TBL] [Abstract][Full Text] [Related]
19. Expanding members and roles of the calpain superfamily and their genetically modified animals.
Sorimachi H; Hata S; Ono Y
Exp Anim; 2010; 59(5):549-66. PubMed ID: 21030783
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the structure of calpain-10 and its interaction with the protease inhibitor SNJ-1715.
da Silva RC; de Alencar NA; Alves CN; Lameira J
Comput Biol Med; 2013 Oct; 43(10):1334-40. PubMed ID: 24034724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
